Geneuro SA

GeNeuro SA is a clinical-stage biopharmaceutical company focused on discovering and advancing therapies for neurodegenerative and autoimmune disorders. Its flagship therapeutic, temelimab, a monoclonal antibody, has successfully completed a Phase IIb clinical trial for multiple sclerosis. This same antibody is currently undergoing Phase IIa studies for type 1 diabetes and has entered Phase I trials for chronic inflammatory demyelinating polyneuropathy. The company actively participates in research and development collaborations, including an agreement with The National Institute of Neurological Disorders and Stroke to develop novel antibody treatments for amyotrophic lateral sclerosis, and partnerships with various academic centers researching inflammatory psychosis. Additionally, GeNeuro holds research collaborations with the International Center for Infectiology Research and Northwestern University, investigating the human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. Founded in 2006, GeNeuro SA's headquarters are located in Plan-les-Ouates, Switzerland.